Tempest Therapeutics (TPST) Non Operating Interest Expenses (2021 - 2025)

Tempest Therapeutics has disclosed Non Operating Interest Expenses across 5 years of filings, most recently posting $46000.0 for Q2 2025.

• In Q2 2025, Non Operating Interest Expenses fell 87.63% year-over-year to $46000.0; the TTM figure through Jun 2026 stood at $46000.0 (down 94.13% YoY), while the FY2025 annual figure was $207000.0, down 84.27% from the prior year.
• Non Operating Interest Expenses came in at $46000.0 for Q2 2025 at Tempest Therapeutics, down from $161000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $464000.0 in Q2 2022 to a low of $46000.0 in Q2 2025.
• Average Non Operating Interest Expenses over 5 years is $326222.2, with a median of $349500.0 recorded in 2023.
• Year-over-year, Non Operating Interest Expenses soared 68.12% in 2022 and slumped 87.63% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $338000.0 in 2021, then gained by 27.81% to $432000.0 in 2022, then slipped by 12.73% to $377000.0 in 2023, then slumped by 34.48% to $247000.0 in 2024, then slumped by 81.38% to $46000.0 in 2025.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $46000.0 in Q2 2025, $161000.0 in Q1 2025, and $247000.0 in Q4 2024.